Belay Diagnostics Announces the Validation of Summit™ 2.0 Comprehensive Genomic Profile Assay in Cerebrospinal Fluid (CSF)
PR Newswire —
Validation Data on 118 Patients Published in Cancers CHICAGO, Feb. 18, 2026 /PRNewswire/ -- Belay Diagnostics, an innovative CLIA/CAP accredited laboratory focused on the development and commercialization of molecular diagnostics targeting central nervous system (CNS) cancers, announced...